window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 2, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

neuroendocrine tumours

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    First patients dosed in Phase 1 trial of DLL3-targeted radiopharmaceutical for small cell lung cancer

    The first patients have been dosed with MP0712, a DLL3-targeted [...]

    July 3, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    UK approves cabozantinib Ipsen for previously treated advanced neuroendocrine tumours

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • European HIV survey finds gap in long-acting treatment conversations
    Categories: Clinical & Regulatory
  • ThinkSono wins FDA clearance for AI-guided ultrasound software for suspected DVT
    Categories: Clinical & Regulatory, Digital & Data, Medical devices
  • ProMIS reports no ARIA-E in Phase 1b Alzheimer’s trial of PMN310
    Categories: Central Nervous System, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top